These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17315755)

  • 21. The placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Stoessl AJ
    Trends Neurosci; 2002 Jun; 25(6):302-6. PubMed ID: 12086748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teaching neurons to respond to placebos.
    Benedetti F; Frisaldi E; Carlino E; Giudetti L; Pampallona A; Zibetti M; Lanotte M; Lopiano L
    J Physiol; 2016 Oct; 594(19):5647-60. PubMed ID: 26861164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subthalamic nucleus stimulation and lesioning have distinct state-dependent effects upon striatal dopamine metabolism.
    Walker RH; Koch RJ; Moore C; Meshul CK
    Synapse; 2009 Feb; 63(2):136-46. PubMed ID: 19021215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saccadometry: a novel clinical tool for quantification of the motor effects of subthalamic nucleus stimulation in Parkinson's disease.
    Temel Y; Visser-Vandewalle V; Carpenter RH
    Exp Neurol; 2009 Apr; 216(2):481-9. PubMed ID: 19320006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placebo responses in Parkinson's disease.
    Lou JS
    Int Rev Neurobiol; 2020; 153():187-211. PubMed ID: 32563288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation.
    Taylor Tavares AL; Jefferis GS; Koop M; Hill BC; Hastie T; Heit G; Bronte-Stewart HM
    Mov Disord; 2005 Oct; 20(10):1286-98. PubMed ID: 16001401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease.
    Kerkerian-Le Goff L; Bacci JJ; Jouve L; Melon C; Salin P
    Brain Res Bull; 2009 Feb; 78(2-3):80-4. PubMed ID: 18790021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.
    Strafella AP; Ko JH; Monchi O
    Neuroimage; 2006 Jul; 31(4):1666-72. PubMed ID: 16545582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease.
    de la Fuente-Fernández R
    Parkinsonism Relat Disord; 2004 Mar; 10(3):125-7. PubMed ID: 15036165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S18-23. PubMed ID: 17702631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Deep brain stimulation for Parkinson's disease and dystonia].
    Yokochi F
    Brain Nerve; 2009 Apr; 61(4):473-83. PubMed ID: 19378817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of deep brain stimulation.
    Benazzouz A; Hallett M
    Neurology; 2000; 55(12 Suppl 6):S13-6. PubMed ID: 11188968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
    Sgambato-Faure V; Cenci MA
    Prog Neurobiol; 2012 Jan; 96(1):69-86. PubMed ID: 22075179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The biochemical bases for reward. Implications for the placebo effect.
    De La Fuente-Fernández R; Stoessl AJ
    Eval Health Prof; 2002 Dec; 25(4):387-98. PubMed ID: 12449082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
    Alegret M; Valldeoriola F; Martí M; Pilleri M; Junqué C; Rumià J; Tolosa E
    Mov Disord; 2004 Dec; 19(12):1463-9. PubMed ID: 15390065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of the placebo effect and of conditioning.
    Haour F
    Neuroimmunomodulation; 2005; 12(4):195-200. PubMed ID: 15990450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine release in human ventral striatum and expectation of reward.
    de la Fuente-Fernández R; Phillips AG; Zamburlini M; Sossi V; Calne DB; Ruth TJ; Stoessl AJ
    Behav Brain Res; 2002 Nov; 136(2):359-63. PubMed ID: 12429397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.